Gsk (GSK) EBT Margin (2016 - 2025)
Historic EBT Margin for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to 28.74%.
- Gsk's EBT Margin rose 279400.0% to 28.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.71%, marking a year-over-year increase of 56700.0%. This contributed to the annual value of 11.08% for FY2024, which is 89100.0% down from last year.
- As of Q3 2025, Gsk's EBT Margin stood at 28.74%, which was up 279400.0% from 23.63% recorded in Q2 2025.
- Gsk's 5-year EBT Margin high stood at 29.12% for Q1 2022, and its period low was 0.8% during Q3 2024.
- Over the past 5 years, Gsk's median EBT Margin value was 20.06% (recorded in 2021), while the average stood at 19.93%.
- Per our database at Business Quant, Gsk's EBT Margin tumbled by -211800bps in 2024 and then soared by 279400bps in 2025.
- Quarter analysis of 5 years shows Gsk's EBT Margin stood at 4.28% in 2021, then skyrocketed by 395bps to 21.18% in 2022, then skyrocketed by 30bps to 27.56% in 2023, then plummeted by -32bps to 18.69% in 2024, then soared by 54bps to 28.74% in 2025.
- Its EBT Margin was 28.74% in Q3 2025, compared to 23.63% in Q2 2025 and 28.05% in Q1 2025.